Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
Launched by EFFERON JSC · Apr 25, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Efferon CT Hemoadsorption trial is studying a new treatment that aims to help patients suffering from cardiogenic shock, which is a serious condition that can occur after a heart attack. In this trial, researchers will use a special device that filters the blood to remove harmful substances that can cause inflammation and damage to other organs. The goal is to see if this treatment can help prevent further organ failure in patients who have had a heart attack and are experiencing cardiogenic shock.
To participate in the trial, patients must be diagnosed with cardiogenic shock within four hours and be in a certain stage of the condition. They should also be in a stable enough condition to receive treatment for at least four hours. However, not everyone can join; for example, those with specific heart conditions or serious health issues like advanced kidney disease will be excluded. If eligible, participants can expect to receive the blood-filtering treatment and be closely monitored for their health during the study. This trial represents an important step in exploring new ways to support patients experiencing this critical situation.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Not more than 4 hours after diagnosis Cardiogenic shock complicating acute myocardial infarction
- • Stages B - C of cardiogenic shock according to SCAI
- • Patient condition allows treatment with Efferon® CT device for at least 4 hours
- • SOFA score 12 or less
- Exclusion Criteria:
- • Broken-heart syndrome (takotsubo cardiomyopathy)
- • Postcardiotomy cardiogenic shock
- • Acute myocardial infarction within the last 4 weeks
- • Myocarditis
- • Cardiac trauma
- • Charlson comorbidity index greater than 9 points
- • Chronic kidney disease, stage 5 D (requiring continuous hemodialysis)
- • Acute pulmonary embolism
- • Acute cerebral circulatory collapse
- • Transfusion reaction
- • Patients on immunosuppressive therapy for cancer and autoimmune diseases
- • Pregnancy
- • Any other clinical condition of the patient that in the opinion of the investigator precludes inclusion in this study
About Efferon Jsc
Efferon JSC is a dynamic clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the healthcare sector. With a strong focus on rigorous research methodologies and patient-centric approaches, Efferon JSC collaborates with leading healthcare professionals and institutions to conduct high-quality clinical trials. The company is committed to ensuring the safety and efficacy of its investigational products, leveraging cutting-edge technology and data analytics to facilitate efficient trial management and regulatory compliance. Efferon JSC aims to contribute significantly to the development of groundbreaking treatments that improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tomsk, , Russian Federation
Patients applied
Trial Officials
Vyacheslav Ryabov, PhD, MD
Principal Investigator
Tomsk NRMC Cardiology Research Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported